Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Ranica – page 220

2 668 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ranica at a glance
2 668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 668 trials in Ranica

Open in trial search

Bladder cancer

Not recruiting

Study of Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Ospedale San Raffaele S.r.l.

Neoplasm

Not recruiting

Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Metastatic malignant melanoma

Not recruiting

Study on Nemvaleukin Alfa and Pembrolizumab for Patients with Advanced Skin or Mucosal Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Endometrial cancer+2

Not recruiting

Study on Selinexor as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Selinexor
  • Sponsor:Karyopharm Therapeutics Inc.

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effects of Durvalumab, Tremelimumab, and Bevacizumab in Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Aveo Pharmaceuticals Inc.

Nasopharyngeal cancer

Not recruiting

Study of Pembrolizumab and Olaparib for Adults with Recurrent or Metastatic, Platinum-Resistant Nasopharyngeal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Fondazione GONO Plus

Glomerulonephritis membranous

Not recruiting

Study of Obinutuzumab for Patients with Primary Membranous Nephropathy Resistant or Intolerant to Rituximab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Viral myocarditis

Not recruiting

Study on Anakinra for Treating Virus-Negative Myocarditis in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Ospedale San Raffaele S.r.l.

Basal cell carcinoma

Not recruiting

Study on Sonidegib for Patients with Locally Advanced Basal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sonidegib
  • Sponsor:Fondazione GONO Plus

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Pfizer Inc.

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

  • IC-MPGN Treatment Evaluation
  • C3 Glomerulopathy Research
  • Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

  • Primary Membranous Nephropathy
  • IgA Nephropathy Interventions
  • Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

  • Disease Progression Prevention
  • Hyperkalemia Management
  • Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.